Takeda re-submits Nesina and Nesina plus Actos at FDA for Type 2 Diabetes - 31-Jul-2012

Takeda has re-filed new drug applications at the FDA for its antidiabetic Nesina (alogliptin) and a fixed-dose combination of the dipeptidyl peptidase IV inhibitor with pioglitazone (Takeda's Actos).Updated additional postmarketing data from outside the US (from Japan) and significant new data from three Phase III studies in its ongoing global clinical trial programme had been included in the resubmissions.

Related News

Related Diabetes and Endocrinology Information

Related Diabetes and Endocrinology Drugs

Back to top

Latest News

10 May 2015
24 May 2013
24 May 2013